We are heading across the pond to to #London for Jefferies London Healthcare Conference. Our CEO, Jak Knowles, CFO, Kathy Bergsteinsson, and CSO, Loïc VINCENT, will share our latest advancements in #cancer research and #Tcell therapies targeting #tp53 and #KRAS mutations during 1X1 meetings. Connect with them to discuss how we’re working to advance precision #immunotherapies to bring potentially curative treatments to patients facing some of the most difficult-to-treat #solidtumor cancers. #JefferiesHealthcare
Affini-T Therapeutics
Biotechnology Research
Watertown, Massachusetts 10,136 followers
Right Targets. Right Cells. Right Place. Unlocking the power of T cells against oncogenic driver mutations.
About us
Affini-T is a leading clinical stage precision immunotherapy company targeting oncogenic driver mutations, beginning with KRAS, to develop potentially curative therapies for patients with solid tumors. We are advancing two distinct T Cell Receptor (TCR) based therapeutic modalities encompassing adoptive cellular therapies and bispecific T Cell Engagers, each designed to harness T cell immunity with unprecedented precision and potency against solid tumors. Our most advanced TCR T-cell therapies are built based on state-of-the-art engineering, synthetic biology, and gene editing proprietary platforms overcoming the challenges of addressing solid tumors. Our T Cell therapies have high specificity and the multi-faceted ability to strike and persist within the solid tumors. Building on the world-class innovation inherent in our leadership team, founders and differentiating technologies, we are powered to develop transformational medicines that last.
- Website
-
https://www.affinittx.com/
External link for Affini-T Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
100 Forge Rd
Watertown, Massachusetts 02472, US
Employees at Affini-T Therapeutics
Updates
-
We look forward to presenting at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, where we will showcase a Trial-in-Progress poster and three posters with preclinical data from our #oncogenicdriver programs. And for the first time, we will also unveil data for bispecific T cell engagers targeting #KRAS and #TP53. For more details on our poster presentations, please visit: https://bit.ly/3YR0cGq. #SITC24 #SolidTumors #Immunotherapy
-
We’re live in #Anaheim at the AMERICAN SOCIETY FOR HISTOCOMPATIBILITY AND IMMUNOGENETICS (ASHI) 50th Annual Meeting! Stop by and meet with our team during today’s poster session. Details: Poster #203, Platinum Ballroom, “Integrating US Census Demographic Data with HLA Frequencies to Accelerate Targeted Cell Therapy Patient Enrollment”, Christian Roy, Dirk Nagorsen, and Gregory J Opiteck, https://bit.ly/3NBjzwM. #ASHI2024 #Tcell therapies #solidtumors #HLATyping
-
-
Tuning in to the 4th Annual Needham & Company Private Biotech Company Virtual 1x1 Forum? Connect with our CEO, Jak Knowles, and CFO, Kathy Bergsteinsson, to learn more about our work to target the most frequent #oncogenicdriver mutations in #solidtumors including #KRAS, #TP53 and #PIK3CA. #biotech
-
Our CEO, Jak Knowles, joined a dynamic panel discussion titled, “The State of Bispecific and New Approaches in Development” alongside Zhen Su, MD MBA, CEO of Marengo Therapeutics, and Ramin Farzaneh-Far, CMO of Capstan Therapeutics. The conversation took place during the Goldman Sachs Cell Therapy Day event in #NewYork, moderated by Goldman Sachs Research team members Elizabeth W. and Paul Choi.
A special thanks to the Goldman Sachs research team for the kind invitation to join the Cell Therapy Day to showcase our Novel TCR Vbeta Bi-specific platform for precision in vivo T cell activation/expansion. Elizabeth W. Paul Choi Salveen Richter Chris Shibutani MD MBA Sonia Gupta Also, really nice to reconnect with peer companies who are also at the forefront of developing next wave T cell targeted technologies. Jak Knowles at Affini-T Therapeutics and Ramin Farzaneh-Far at Capstan Therapeutics. Marengo Therapeutics
-
-
We are excited to meet with industry leaders, peers, and investors at three events today. If you’re attending any of these conferences and would like to learn more about our work advancing #TCRT #precisionimmunotherapies for patients with #solidtumors, please reach out to us. We look forward to connecting with you! RBC Capital Markets | Chardan | Goldman Sachs #ChardanGMConf #CellTherapy
-
Gary Shapiro, our VP, Discovery Biology, is presenting today at the 22nd Annual Discovery on Target event in #Boston. Learn more about his presentation here: https://bit.ly/3ZIMd6s. #BostonDOT24 #drugdiscovery #solidtumors
-
-
Today, our CEO, Jak Knowles, and CFO, Kathy Bergsteinsson, will be at the Bank of America Healthcare Trailblazers Private Company Conference in #Boston. Connect with them to learn more about our recent progress and pipeline of #precisionimmunotherapies for #solidtumors. #TCRT
-
Attending the 9th Annual CAR-TCR Summit in Boston today and tomorrow? You’ll have several opportunities to listen and meet with team members Patrick Halvey, Damien Hallet, and Gary Shapiro at three presentations and a panel. For more details and a full schedule, head to the event site: https://bit.ly/4dzmL7y #CARTCRSummit #solidtumors #Tcelltherapies #KRAS #tp53
-
Kathy Bergsteinsson, our CFO, will be at Cantor Fitzgerald’s 2024 Global Healthcare Conference in #NewYork today where she’ll participate in 1:1 meetings. Connect with her to learn more about our work to develop #KRAS-targeting precision #immunotherapies for patients with #solidtumors. #CantorHCC
-